New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer

Cancer Treatment Reviews

Volumn 45, Issue , 2016, Pages 87-96

  Yang, Sherry X ^a   Polley, Eric ^a,b   Lipkowitz, Stanley ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Breast cancer; Chemotherapy; HER2; Paclitaxel; PAKT; PIK3CA mutations

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; FORKHEAD TRANSCRIPTION FACTOR; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4 BISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; DISEASE FREE SURVIVAL; DRUG ACTIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; MOLECULAR INTERACTION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER STAGING; FEMALE; GENETICS; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; MUTATION; NEOPLASM STAGING; ONCOGENE PROTEIN V-AKT; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84960946714     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.03.004     Document Type: Review

References (103)

1. Whitman M., Downes C.P., Keeler M., Keller T., Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 1988, 332:644-646.
2. Comprehensive molecular portraits of human breast tumours Nature 2012, 490:61-70.
3. Davies C., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784.
4. Dowsett M., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28:509-518.
5. Slamon D.J., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
6. Wolff A.C., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/College of American pathologists clinical practice guideline update. J Clin Oncol 2013, 31:3997-4013.
7. Slamon D., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365:1273-1283.
8. Carey L.A., et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006, 295:2492-2502.
9. Onitilo A.A., Engel J.M., Greenlee R.T., Mukesh B.N. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009, 7:4-13.
10. Cheang M.C., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750.
11. Franke T.F., Kaplan D.R., Cantley L.C., Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997, 275:665-668.
12. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
13. Badve S., Nakshatri H. Role of AKT isotypes in breast cancer. J Pathol 2013, 229:e1.
14. Goold R.G., Owen R., Gordon-Weeks P.R. Glycogen synthase kinase 3beta phosphorylation of microtubule-associated protein 1B regulates the stability of microtubules in growth cones. J Cell Sci 1999, 112(Pt 19):3373-3384.
15. Brunet A., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
16. Osborne C.K., Schiff R., Fuqua S.A., Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001, 7:4338s-4342s. discussion 4411s-4412s.
17. Hollander M.C., Blumenthal G.M., Dennis P.A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011, 11:289-301.
18. Clark A.S., West K., Streicher S., Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002, 1:707-717.
19. Swanton C., et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007, 11:498-512.
20. Brown K.K., Montaser-Kouhsari L., Beck A.H., Toker A. MERIT40 is an Akt substrate that promotes resolution of DNA damage induced by chemotherapy. Cell Rep 2015, 11:1358-1366.
21. Samuels Y., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
22. Pang B., et al. Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis. Sci Rep 2014, 4:6255.
23. Saal L.H., et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65:2554-2559.
24. Karakas B., Bachman K.E., Park B.H. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006, 94:455-459.
25. Stemke-Hale K., et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091.
26. Ellis M.J., et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 2010, 119:379-390.
27. Loi S., et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 2010, 107:10208-10213.
28. McShane L.M., Korn E.L., Freidlin B. Handbook of therapeutic biomarkers in cancer 2013, 1-490. Pan Stanford Publishing Pte. Ltd, Singapore. S.X. Yang, J.E. Dancey (Eds.).
29. Perez-Tenorio G., et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007, 13:3577-3584.
30. Maruyama N., et al. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007, 13:408-414.
31. Kalinsky K., et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009, 15:5049-5059.
32. Badve S., et al. Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. Am J Pathol 2010, 176:2139-2149.
33. Sabine V.S., et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol 2014, 32:2951-2958.
34. Zardavas D., et al. Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC). J Clin Oncol 2015, 33.
35. Mayer I.A., Arteaga C.L. PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor-positive breast cancer?. J Clin Oncol 2014, 32:2932-2934.
36. Campbell R.A., et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001, 276:9817-9824.
37. Bosch A., et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med 2015, 7:283ra51.
38. Aleskandarany M.A., et al. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res Treat 2011, 127:407-416.
39. Andre F., et al. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol 2008, 19:315-320.
40. Hartog H., et al. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res Treat 2011, 129:725-736.
41. Yang S.X., et al. Prognostic significance of PAKT plus estrogen receptor status in adjuvant cytotoxic treatment of breast cancer. Eur J Cancer (Suppl.) 2012, 48:148.
42. Lopez-Knowles E., et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010, 126:1121-1131.
43. Andreopoulou E., Sparano J.A. Chemotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer: an overview. Curr Breast Cancer Rep 2013, 5:42-50.
44. Knuefermann C., et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22:3205-3212.
45. Li X., Lu Y., Liang K., Liu B., Fan Z. Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res 2005, 7:R589-R597.
46. Polley M.Y., et al. Statistical and practical considerations for clinical evaluation of predictive biomarkers. J Natl Cancer Inst 2013, 105:1677-1683.
47. Liedtke C., et al. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res 2008, 10:R27.
48. Nakayama S., et al. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res 2009, 11:R12.
49. Mamounas E.P., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23:3686-3696.
50. Yang S.X., et al. Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol 2010, 28:2974-2981.
51. Hutchinson L. P-AKT predicts paclitaxel benefit. Nat Rev Clin Oncol 2010, 7:423.
52. Kawase T., et al. PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell 2009, 136:535-550.
53. Asakuma J., Sumitomo M., Asano T., Asano T., Hayakawa M. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 2003, 63:1365-1370.
54. Franke T.F., Kaplan D.R., Cantley L.C. PI3K: downstream AKTion blocks apoptosis. Cell 1997, 88:435-437.
55. Bartlett J.M., et al. Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. Breast Cancer Res Treat 2013, 138:773-781.
56. Ellis P., et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009, 373:1681-1692.
57. Henderson I.C., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976-983.
58. Bear H.D., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 2006, 24:2019-2027.
59. Berns K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
60. Eichhorn P.J., et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008, 68:9221-9230.
61. Hanker A.B., et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A 2013, 110:14372-14377.
62. Pierga J.Y., et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 2010, 122:429-437.
63. Cizkova M., et al. Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer 2013, 108:1807-1809.
64. Jensen J.D., et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 2012, 23:2034-2042.
65. Baselga J., et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 2014, 32:3753-3761.
66. Esteva F.J., et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010, 177:1647-1656.
67. Baselga J., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640.
68. Majewski I.J., et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol 2015, 33:1334-1339.
69. Nuciforo P.G., et al. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Ann Oncol 2015, 26:1494-1500.
70. Untch M., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010, 28:2024-2031.
71. von Minckwitz G., et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)dagger. Ann Oncol 2014, 25:2363-2372.
72. von Minckwitz G., et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014, 15:747-756.
73. Loibl S., et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014, 32:3212-3220.
74. Henry N.L., Schott A.F., Hayes D.F. Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility. J Clin Oncol 2014, 32:3207-3209.
75. Guarneri V., et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012, 30:1989-1995.
76. Guarneri V., et al. Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer. Oncologist 2015.
77. Loibl S., et al. Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: combined analysis of 967 patients from three prospective clinical trials. J Clin Oncol 2015, 33(Suppl). Abstr 511.
78. Slamon D.J., et al. Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3. J Clin Oncol 2015, 33(suppl). abstr 512.
79. Hurvitz S.A., et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol 2015, 16:816-829.
80. Andre F., et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014, 15:580-591.
81. Joensuu H., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
82. Loi S., et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 2013, 105:960-967.
83. Pogue-Geile K.L., et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 2015, 33:1340-1347.
84. Eiermann W., et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 2011, 29:3877-3884.
85. Stern H.M., et al. PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance. Clin Cancer Res 2015, 21:2065-2074.
86. Baselga J., et al. Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC). Cancer Res 2013, (supple). abstr LB-63.
87. Anderson W.F., et al. Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat 2009, 113:189-196.
88. Early Breast Cancer Trialists' Collaborative G, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379:432-444.
89. MacKeigan J.P., et al. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 2002, 8:2091-2099.
90. Nakashio A., Fujita N., Rokudai S., Sato S., Tsuruo T. Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 2000, 60:5303-5309.
91. Ramos J., Sirisawad M., Miller R., Naumovski L. Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation. Mol Cancer Ther 2006, 5:1176-1182.
92. O'Brien N.A., et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010, 9:1489-1502.
93. Generali D., et al. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 2008, 14:2673-2680.
94. Barbareschi M., et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007, 13:6064-6069.
95. Dupont Jensen J., et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 2011, 17:667-677.
96. Ramirez-Ardila D.E., et al. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res Treat 2013, 139:39-49.
97. Beelen K., et al. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Res 2014, 16:R13.
98. Stal O., et al. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 2003, 5:R37-R44.
99. Kirkegaard T., et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005, 207:139-146.
100. Cicenas J., et al. Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res 2005, 7:R394-R401.
101. Tokunaga E., et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006, 13:137-144.
102. Cizkova M., et al. PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Breast Cancer Res 2012, 14:R28.
103. Bostner J., et al. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat 2013, 137:397-406.